TuHURA Biosciences
TAMPA, Florida, United States · Biotechnology, Healthcare, Health Care
Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s technologies are designed to overcome primary and acquired resistance to checkpoint inhibitors or cellular therapies in the treatment of cancer.
Key facts
- Headquarters
- TAMPA, Florida, United States
- Employees
- 23
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Private
- Website
- tuhurabio.com
- Company page
Recent activity at TuHURA Biosciences
- : TuHURA Biosciences Appoints Dr. Craig L. Tendler as Chief Medical Officer
- : TuHURA Biosciences, Inc. secures $12.5 million in a private equity financing to advance cancer immunotherapy treatments, with an additional $3.0 million from warrant exercises.
- : TuHURA Appoints Bertrand Le Bourdonnec as Executive Vice President
- : TuHURA Biosciences Enters Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
- : MORPHOGENESIS
- : MORPHOGENESIS INC
- : MORPHOGENESIS INC
- : Kintara Therapeutics, Inc.
- : MORPHOGENESIS INC
- : MORPHOGENESIS INC
TuHURA Biosciences funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2025 | Private Equity | $12.5M |
| Dec 2023 | Seed | $1.7M |
| Nov 2021 | Venture | $5.1M |
| Dec 2020 | Seed | $2.7M |
| Aug 2020 | Venture | $21.8M |
Leadership
- James Bianco, Executive Officer, Director
- George Ng, Director
- Kiran Patel, Director
- Saiid Zarrabian, Executive Officer, Director
- John Liatos, Executive Officer, Director
- Robert Hoffman, Director
- Robert Toth, Director
- Laura Johnson, Director
- Keith Murphy, Director
Verified email and direct lines for TuHURA Biosciences’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
TuHURA Biosciences in the news
- TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering - PR Newswire (Dec 09, 2025)
- TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology - PR Newswire (Oct 05, 2026)
- TuHURA Biosciences (HURA) Stock Price, News & Analysis - MarketBeat (Nov 05, 2024)
- TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire (Sep 08, 2026)
- TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers - PR Newswire (Sep 14, 2026)
- TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma - PR Newswire (Feb 02, 2026)
- TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy - PR Newswire (Jun 03, 2025)
- TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone - PR Newswire (Dec 15, 2025)
Companies similar to TuHURA Biosciences
- Ovid Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Werewolf Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Tempest Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Oncotelic Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- CytoDyn · Biotechnology, Healthcare, Health Care, Therapeutics
About TuHURA Biosciences: questions and answers
What does TuHURA Biosciences do?
Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s technologies are designed to overcome primary and acquired resistance to checkpoint inhibitors or cellular therapies in the treatment of cancer.
Where is TuHURA Biosciences headquartered?
TuHURA Biosciences is headquartered in TAMPA, Florida, United States.
How many employees does TuHURA Biosciences have?
TuHURA Biosciences has about 23 employees.
Has TuHURA Biosciences raised funding?
Yes. Fundz has recorded 5 funding events for TuHURA Biosciences. The most recent, Private Equity of $12.5M, was in Jun 2025.
What is the latest news on TuHURA Biosciences?
On Mar 23, 2026, TuHURA Biosciences Appoints Dr. Craig L. Tendler as Chief Medical Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy